UT Arlington Research Team’s Work Could Lead To Earlier Diagnosis, Treatment Of Mental Diseases

August 17, 2014

Herb Booth, University of Texas, Arlington

A computer science and engineering associate professor and her doctoral student graduate are using a genetic computer network inference model that eventually could predict whether a person will suffer from bipolar disorder, schizophrenia or another mental illness.

The findings are detailed in the paper Inference of SNP-Gene Regulatory Networks by Integrating Gene Expressions and Genetic Perturbations, which was published in the June edition of Biomed Research International. The principal investigators were Jean Gao, an associate professor of computer science and engineering, and Dong-Chul Kim, who recently earned his doctorate in computer science and engineering from UT Arlington.

We looked for the differences between our genetic computer network and the brain patterns of 130 patients from the University of Illinois, Gao said. This work could lead to earlier diagnosis in the future and treatment for those patients suffering from bipolar disorder or schizophrenia. Early diagnosis allows doctors to provide timely treatments that may speed up aid to help affected patients.

The UT Arlington researchers teamed with Jiao Wang of the Beijing Genomics Institute at Wuhan, China; and Chunyu Liu, visiting associate professor at the University of Illinois Department of Psychiatry, on the project.

Gao said the findings also could lead to more individualized drug therapies for those patients in the early stages of mental illnesses.

Our work will allow doctors to analyze a patients genetic pattern and apply the appropriate levels of personalized therapy based on patient-specific data, Gao said.

One key to the research is designing single nucleotide polymorphism or SNP networks, researchers said.

SNPs are regulators of genes, said Kim, who joins the University of Texas-Pan American this fall as an assistant professor. Those SNPs visualize how individual genes will act. It gives us more of a complete picture.

See the original post:
UT Arlington Research Team's Work Could Lead To Earlier Diagnosis, Treatment Of Mental Diseases

Researchers block plant hormone: Small molecule inhibits jasmonic acid, helps to explain its effects

5 minutes ago Jarin1 inhibits the enzyme JAR1 by displacing the natural substrate, Jasmonoyl-isoleucine (JA-Ile), from its binding site. Both substances overlap, so that JAR1 can no longer fulfil its tasks. The left panel shows an overview of the entire enzyme; the right panel a view into the active centre. Credit: Corey S. Westfall, Washington University, St. Louis

Researchers trying to get new information about the metabolism of plants can switch off individual genes and study the resulting changes. However, Erich Kombrink from the Max Planck Institute for Plant Breeding Research in Cologne and Markus Kaiser from the University of Duisburg-Essen adopt a different approach. They identify small molecules that block specific components of the metabolic process like brake pads and prevent the downstream reactions. In their search for these molecules, they use a biological selection process involving intact plants. This strategy has long been exploited in drug research. Its application in the plant sciences, however, is relatively new.

Kombrink, Kaiser and their colleagues have identified a molecule that interferes with the effect of jasmonic acid. This plant hormone influences flower formation, root growth, defence against herbivores and infections, wound healing, ageing of plants, and much more.

Although many questions about plant metabolism can be answered through targeted gene mutations, the method has its limits. This is also demonstrated in the case of jasmonic acid and its derivatives. So far, only one signalling chain has been discovered, but this cannot explain the wide-ranging effect of this plant hormone. Therefore, other hitherto undiscovered signalling paths and action mechanisms must exist. To find out more about them, Kombrink and Kaiser have adopted an approach that is similar to one used in medicine. Their strategy is based on the blocking of important metabolic pathways using low molecular weight compounds, which are easily assimilated by the plant. While in medical therapy such compounds are assimilated through the blood, in the plant they are introduced through the root.

The scientists embarked on their search with a screening of Arabidopsis thaliana and treating the plants with compounds in such a way that the desired selection could be identified by a conspicuous trait. Of the 1728 substances from a commercial compound library tested 16 emerged as inhibitors. This number was further reduced using more selective tests. In the end, only one substance turned out to be a specific inhibitor of the jasmonic acid signalling pathway and was given the name Jarin-1. "In terms of its basic structure, the substance is a plant alkaloid, whose two amino groups can carry different side chains," Kombrink explains. "However, its effect is associated with a particular side chain in one of the positions. Other side chains impair the activity of the substance. We also deliberately synthesised it once again to be certain that we had understood its chemical structure correctly."

The scientists also looked for the target of the newly discovered inhibitor. The known signalling chain starts with the conjugation of the jasmonic acid with the amino acid isoleucine by an enzyme called JAR1. The resulting pair leads to the expression following various detours of the genes necessary for the relevant effect of the jasmonic acid. Kombrink and Kaiser were able to show that JAR1 is the target of the newly discovered inhibitor. Due to the inhibition, the jasmonic acid conjugated with isoleucine does no longer accumulate in the cell. As a result genes are not expressed because the jasmonic acidisoleucine pair no longer activates the genes' starting point.

The Jarin-1 inhibitor identified by Kombrink and Kaiser not only works in Arabidopsis but also in Cardamine hirsuta or hairy bittercress. "So we are obviously dealing with a broadly applicable molecule," comments Kombrink. Under the effect of the inhibitor, the plants show the same features as they do following the targeted mutation of genes from the jasmonic acid signalling pathway.

The scientists also investigated the exact location where the molecule takes effect. They succeeded in demonstrating that it binds to the active centre of JAR1 and inhibits the natural substrate. "Our molecule is not a classical competitive inhibitor," says Kombrink. "But its effect can be explained, at least in parts, by displacement of the substrate from its binding site."

Small molecules are interesting new tools for plant research. Through their work, the researchers show how it is possible to search for them systematically and to identify their molecular mode of action.

Explore further: Signalling pathway links local and systemic plant immunity

See the original post here:
Researchers block plant hormone: Small molecule inhibits jasmonic acid, helps to explain its effects

Study finds women seek anti-aging clinicians to treat menopausal symptoms

PUBLIC RELEASE DATE:

18-Aug-2014

Contact: Susan Griffith susan.griffith@case.edu 216-368-1004 Case Western Reserve University

Feeling that conventional doctors did not take their suffering seriously, women instead sought out hormonal treatments for menopausal symptoms from anti-aging clinicians, according to a Case Western Reserve University study that investigated the appeal of anti-aging medicine.

Some women also feared the harmful side effects from conventional hormone replacement therapy (HRT) that had shown increased risks for cancer, heart disease and high blood pressure. Yet, they thought that the bioidentical, "natural" hormones their anti-aging doctors prescribed were safe, despite a lack of conventional scientific evidence to that fact.

Michael Flatt, a doctoral candidate in sociology at Case Western Reserve University, and Jennifer Fishman, assistant professor at McGill University, will discuss these and other findings during the presentation "'Hormones Are Where It's At': Bioidentical Hormones, Menopausal Women, and Anti-Aging Medicine" on Monday, Aug. 18, at the 109th Annual Meeting of the American Sociological Association, Aug. 16-19, in San Francisco.

The findings about the women's attitudes are part of a larger study in the Department of Bioethics at Case Western Reserve that investigated the views of scientists, doctors and patients involved with anti-aging science and medicine.

The researchers, who conducted the study with Richard Settersten Jr., professor of public health at Oregon State University, explored what it was about anti-aging medicine that appealed to women, given that the costs for care and prescribed medications were not covered by medical insurance.

Was it vanity to maintain their youthful appearance or some other motivation?

Findings from in-depth interviews with 25 women who used bioidentical hormone replacement therapy (BHRT) prescribed by an anti-aging clinician bucked the vanity-driven stereotype.

Link:
Study finds women seek anti-aging clinicians to treat menopausal symptoms

Man who killed son a schizophrenic: doc

THREE days before Roberto Umpad, 29, killed his two-year-old son, neighbors and relatives had noticed his unusual behaviour.

Hilumon siya ug magsigeg hinuktok (He was very quiet and he looked like he had a lot on his mind), said Odessa Capili, his neighbor.

In 2012, Umpad underwent treatment at the Vicente Sotto Memorial Medical Centers (VSMMC) Center for Behavioral Science after suffering from a nervous breakdown.

Traumatic youth

According to a relative, who asked not to be named, Umpad had a traumatic childhood because his father left him when he was still young while his mother went abroad.

Umpad had been admitted to the psychiatric ward six times.

He last went to the VSMMC on Feb. 14, 2013 for his check-up.

He was supposed to continue his medication but because they had no money, he stopped taking them last year.

Dr. Rene Obra, chief of the Center for Behavioral Sciences, said they diagnosed Umpad with schizophrenia.

The doctor described schizophrenia as a mental illness where a person loses contact with reality and experiences mood disorder symptoms.

More:
Man who killed son a schizophrenic: doc

With attitudes changing, and science shifting, NFL searches for marijuana answers

Marijuana is casting an ever-thickening haze across NFL locker rooms, and it's not simply because more players are using it.

As attitudes toward the drug soften, and science slowly teases out marijuana's possible benefits for concussions and other injuries, the NFL is reaching a critical point in navigating its tenuous relationship with what is recognized as the analgesic of choice for many of its players.

"It's not, let's go smoke a joint," retired NFL defensive lineman Marvin Washington said. "It's, what if you could take something that helps you heal faster from a concussion, that prevents your equilibrium from being off for two weeks and your eyesight for being off for four weeks?"

One challenge the NFL faces is how to bring marijuana into the game as a pain reliever without condoning its use as a recreational drug. And facing a lawsuit filed on behalf of hundreds of former players complaining about the effects of prescription painkillers they say were pushed on them by team trainers and doctors, the NFL is looking for other ways to help players deal with the pain from a violent game.

A Gallup poll last year found 58 percent of Americans believe marijuana should be legalized. That's already happened in Colorado and Washington the states that are home of last season's Super Bowl teams.

The World Anti-Doping Agency has said it does not need to catch out-of-competition marijuana users. And at least one high-profile coach, Pete Carroll of the champion Seahawks, publicly said he'd like to see the NFL study whether marijuana can help players.

There are no hard numbers on how many NFL players are using marijuana, but anecdotal evidence, including the arrest or league discipline of no fewer than a dozen players for pot over the past 18 months, suggests use is becoming more common.

Washington Redskins defensive back Ryan Clark didn't want to pinpoint the number of current NFL players who smoke pot but said, "I know a lot of guys who don't regularly smoke marijuana who would use it during the season."

Washington wouldn't put a specific number on it but said he, too, knew his share of players who weren't shy about lighting up when he was in the league, including one guy "who just hated the pain pills they were giving out at the time." Another longtime defensive lineman, Marcellus Wiley, estimates half the players in the average NFL locker room were using it by the time he shut down his career in 2006.

"They are leaning on it to cope with the pain," said Wiley, who played defensive line in the league for 10 seasons. "They are leaning on it to cope with the anxiety of the game."

Read this article:
With attitudes changing, and science shifting, NFL searches for marijuana answers

Volokh Conspiracy: Consumer Credit and the American Economy

By Todd Zywicki August 14

I am excited to say that after years of work my new co-authored book Consumer Credit and the American Economy is now officially available for sale. The Amazon page is here. It is co-authored with former Federal Reserve economist Thomas Durkin, current Fed economist Gregory Elliehausen, and University of Arizona professor Michael Staten (who was formerly head of the Credit Research Center and Financial Services Research Program). The book is a comprehensive look at the economics, regulation, history, and intellectual history of consumer credit in America (largely excluding mortgage credit, however, which we decided is really a book unto itself).

One of the joys of working with my co-authors was how much I learned about these topics, especially the intellectual history of the study of consumer credit. The book is dedicated to the pioneers in the field, who are largely forgotten today, but whose basic analytical framework remains almost entirely as valid today as it was when first developed almost a century ago.

Tom and I plan to do a series of posts sometime soon highlighting some of the key points of the book. But for now Ill just post the Amazon summary and cover blurbs to give you a flavor:

Consumer Credit and the American Economyexamines the economics, behavioral science, sociology, history, institutions, law, and regulation of consumer credit in the United States.

After discussing the origins and various kinds of consumer credit available in todays marketplace, this book reviews at some length the long run growth of consumer credit to explore the widely held belief that somehow consumer credit has risen too fast for too long. It then turns to demand and supply with chapters discussing neoclassical theories of demand, new behavioral economics, and evidence on production costs and why consumer credit might seem expensive compared to some other kinds of credit like government finance. This discussion includes review of the economics of risk management and funding sources, as well discussion of the economic theory of why some people might be limited in their credit search, the phenomenon of credit rationing. This examination includes review of issues of risk management through mathematical methods of borrower screening known as credit scoring and financial market sources of funding for offerings of consumer credit.

The book then discusses technological change in credit granting. It examines how modern automated information systems called credit reporting agencies, or more popularly credit bureaus, reduce the costs of information acquisition and permit greater credit availability at less cost. This discussion is followed by examination of the logical offspring of technology, the ubiquitous credit card that permits consumers access to both payments and credit services worldwide virtually instantly.

After a chapter on institutions that have arisen to supply credit to individuals for whom mainstream credit is often unavailable, including payday loans and other small dollar sources of loans, discussion turns to legal structure and the regulation of consumer credit. There are separate chapters on the theories behind the two main thrusts of federal regulation to this point, fairness for all and financial disclosure. Following these chapters, there is another on state regulation that has long focused on marketplace access and pricing.

Before a final concluding chapter, another chapter focuses on two noncredit marketplace products that are closely related to credit. The first of them, debt protection including credit insurance and other forms of credit protection, is economically a complement. The second product, consumer leasing, is a substitute for credit use in many situations, especially involving acquisition of automobiles. This chapter is followed by a full review of consumer bankruptcy, what happens in the worst of cases when consumers find themselves unable to repay their loans.

Because of the importance of consumer credit in consumers financial affairs, the intended audience includes anyone interested in these issues, not only specialists who spend much of their time focused on them. For this reason, the authors have carefully avoided academic jargon and the mathematics that is the modern language of economics. It also examines the psychological, sociological, historical, and especially legal traditions that go into fully understanding what has led to the demand for consumer credit and to what the markets and institutions that provide these products have become today.

Continued here:
Volokh Conspiracy: Consumer Credit and the American Economy

Screening along the spectrum: The search for a genetic test for autism

By Shane Huntington

Neuropsychiatrist Prof Chris Pantelis and neural engineering researcher Prof Stan Skafidas discuss the potential for the use of genetics to improve the diagnosis of autism.

SHANE HUNTINGTON I'm Dr Shane Huntington. Thanks for joining us. Human beings are social animals. We rely on language and the subtle social cues that accompany our words to communicate with each other. But for people with Autism Spectrum Disorder, or ASD for short, the simple acts of communicating and interacting with others in a social setting can be baffling or even terrifying. Currently ASD diagnosis is complex. Psychological assessments and interviews are combined with behavioural observations by parents and teachers and a multitude of other mental disorders need to be carefully ruled out. But we know from twin studies that there's a genetic component to ASD, so why don't we have a genetic test for this condition? Are behavioural observations really the best we can do for desperate parents seeking answers for the challenging behaviour in their children? Surely our extraordinary advances in genetics hint at effective DNA based tests. Today on Up Close we speak to a neuropsychiatrist and an electrical engineer about how we might one day test for ASD based on our genetics. Chris Pantelis is Professor of Neuropsychiatry and Scientific Director of the Melbourne Neuropsychiatry Centre at the University of Melbourne and Melbourne Health. Stan Skafidas is Professor of Neural Engineering at the Department of Electrical and Electronic Engineering; leads the Melbourne School of Engineering's research in nanoelectronics and is the Director of the Centre for Neural Engineering. Welcome to Up Close Stan and Chris.

STAN SKAFIDAS Thank you.

CHRIS PANTELIS Thank you.

SHANE HUNTINGTON Chris, I might start with you. What sorts of tests are currently available to diagnose someone with Autism Spectrum Disorder?

CHRISTOS PANTELIS So the diagnosis of Autism Spectrum Disorder relies very much on clinical observation. It requires careful considered observation of behaviour, social interaction and particularly looking at language and communication; also observations related to stereotype, the repetitive behaviours that many of these children manifest. The disorder is diagnosed early. The onset is before the age of three and it's the observation that children are not engaging, not socialising appropriately, that they're delayed in their language and that they may have stereotyped or repetitive behaviours. So very much the diagnosis is based on clinical observation at this point in time. Now as you rightly point out it is clear that there is a genetic component to this disorder. It runs in families. Those twins that are monozygotic have a high concordance, which means that if one twin has the disorder there's a high likelihood that the co-twin is also affected. This means that we should be able to examine the genetics of this disorder and see if we can come up with a test if you like that might help us in our clinical diagnosis.

SHANE HUNTINGTON You mentioned we can look at children as young as three. It would seem difficult that you'd be able to extract the sort of behavioural anomalies that you're talking about at that age, given the wide variety of developmental speeds that we find out kids growing up with. Now some kids learn language very quick, others don't. How successful is it in terms of determining if a child is positive at age three?

CHRISTOS PANTELIS Again a very good and I think the important thing here is that one needs to take account of the trajectory of development of any individual child. And often clinicians looking at these children will assess them over a lengthy period of time. The diagnosis might be suspected but may not be confirmed for a considerable period of time, perhaps a number of years. It depends on the severity of the presentation, the range of symptoms and how they're developing.

SHANE HUNTINGTON You mentioned the possibility of genetic testing. It would seem that we have a genetic test for every second illness at the moment. There are a lot of new ones around, the most commonly known ones such as those for breast cancer and so forth. There is definitely a genetic component to this as you say from twin studies. Why is it that we don't have a genetics test at this point for autism?

Read more:
Screening along the spectrum: The search for a genetic test for autism

Earlier diagnosis, treatment of mental illness? Genetic computer network inference model

A computer science and engineering associate professor and her doctoral student graduate are using a genetic computer network inference model that eventually could predict whether a person will suffer from bipolar disorder, schizophrenia or another mental illness.

The findings are detailed in the paper "Inference of SNP-Gene Regulatory Networks by Integrating Gene Expressions and Genetic Perturbations," which was published in the June edition of Biomed Research International. The principal investigators were Jean Gao, an associate professor of computer science and engineering, and Dong-Chul Kim, who recently earned his doctorate in computer science and engineering from UT Arlington.

"We looked for the differences between our genetic computer network and the brain patterns of 130 patients from the University of Illinois," Gao said. "This work could lead to earlier diagnosis in the future and treatment for those patients suffering from bipolar disorder or schizophrenia. Early diagnosis allows doctors to provide timely treatments that may speed up aid to help affected patients."

The UT Arlington researchers teamed with Jiao Wang of the Beijing Genomics Institute at Wuhan, China; and Chunyu Liu, visiting associate professor at the University of Illinois Department of Psychiatry, on the project.

Gao said the findings also could lead to more individualized drug therapies for those patients in the early stages of mental illnesses.

"Our work will allow doctors to analyze a patient's genetic pattern and apply the appropriate levels of personalized therapy based on patient-specific data," Gao said.

One key to the research is designing single nucleotide polymorphism or SNP networks, researchers said.

"SNPs are regulators of genes," said Kim, who joins the University of Texas-Pan American this fall as an assistant professor. "Those SNPs visualize how individual genes will act. It gives us more of a complete picture."

The paper is a culmination of four years of work.

Khosrow Behbehani, dean of the College of Engineering, said the research merges the power of computer science and engineering, psychology and genetics.

See the original post here:
Earlier diagnosis, treatment of mental illness? Genetic computer network inference model

Are patients being discharged from hospice care to save money?

PUBLIC RELEASE DATE:

13-Aug-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, August 13, 2014About 1 in 5 Medicare patients is discharged from hospice care alive, whether due to patients' informed choice, a change in their condition, or inappropriate actions by the hospice to save on hospitalization costs related to terminal illness. How live discharge rates differ between hospice programs and geographic regions, and when those rates should raise red flags are among the issues explored in the article "A National Study of Live Discharges from Hospice" , published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers/. The article is available free on the Journal of Palliative Medicine website until September 13, 2014.

Joan M. Teno, MD, Pedro Gozalo, PhD, and Vincent Mor, PhD, Brown University School of Public Health (Providence, RI), and Michael Plotzke, PhD, Abt Associates (Cambridge, MA), examined all of the Medicare hospice discharges in the U.S. between January 1 to December 31, 2010. For the patients discharged alive, they gathered data on survival for up to 6 months, subsequent hospitalizations, and Medicare payments during the 30 days after live hospice discharge. The authors provide details on the substantial variation they found in the rates of live discharges across states and between individual hospices, in particular comparing not-for-profit to for-profit hospice programs and more mature programs versus those that had been in operation for 5 years or less.

"The phenomenon of hospice patients 'graduating' because they get better with hospice care is well known. But, all patients discharged days to weeks before death is very strange," says Charles F. von Gunten, MD, PhD, Editor-in-Chief of Journal of Palliative Medicine and Vice President, Medical Affairs, Hospice and Palliative Medicine for OhioHealth (Columbus, OH).

###

Journal of Palliative Medicine is the official journal of the Center to Advance Palliative Care (CAPC) and an official journal of the Hospice and Palliative Nurses Association.

About the Journal

Journal of Palliative Medicine, published monthly in print and online, is an interdisciplinary journal that reports on the clinical, educational, legal, and ethical aspects of care for seriously ill and dying patients. The Journal includes coverage of the latest developments in drug and non-drug treatments for patients with life-threatening diseases including cancer, AIDS, cardiac disease; pulmonary, neurological, and respiratory conditions; and other diseases. The journal reports on the development of palliative care programs around the United States and the world, and on innovations in palliative care education. Tables of content and a sample issue may be viewed on the Journal of Palliative Medicine website.

Read more:
Are patients being discharged from hospice care to save money?

Tampa dermatologist says SPF a top anti-aging agent

Tampa dermatologist Dr. Seth Forman agrees with the findings in the journal Annals of Internal Medicine that consistent use of SPF (sun-protection factor) can keep your skin looking younger, longer.

In this study conducted by Australian researchers, adults ranging from 25 to 55 had 24 percent less skin aging when using SPF more frequently than men and women who used it on occasion.

The key is protection from ultraviolet rays and sun damage, says Dr. Forman. Not only will SPF help you sustain a youthful look, but it greatly reduces the risks that come from sun exposure.

The study was performed over a 4.5 year span on healthy adults up to age 55 in Australia. Half of the 900 participants were instructed to apply a SPF of 15 or greater to their head, neck, arms and hands, whereas the other half was told to apply sunscreen whenever they wanted to.

According to the Huffington Post, researchers graded the hands of the studys participants on a six-point scale, then re-graded at the end of 4.5 years.

While other factors can come in to play, such as genetics, diet and overall sun exposure, SPF remains a top anti-aging agent, professes the board-certified Tampa dermatologist. I recommend to all of my patients the daily use of a broad-spectrum, SPF 30 sunscreen.

Dr. Forman also suggests using clothing to cover up exposed skin and avoiding the sun when its rays are most powerful, between 10 a.m. and 4 p.m., to slow down the aging process.

Dr. Forman is the founder of Forman Dermatology and Skin institute, located in Tampa, Fla. and has appeared on TV shows across the country, including the nationally syndicated show The Doctors to provide sun-protection tips and to demonstrate his breakthrough skin cancer treatments.

For more on Dr. Seth Forman, Tampa dermatology or Forman Dermatology and Skin Cancer Institute, please visit http://www.FormanDerm.com.

About Dr. Seth Forman:Dr. Forman is a board-certified dermatologist practicing in Tampa, Florida. He was voted the Best Dermatologist in Carrollwood the past three years by the Carrollwood News and Tribune. In December 2011, he opened his newTampa dermatologyoffice, Forman Dermatology and Skin Cancer Institute, where he gives psoriasis sufferers access to the latest treatment options, including topical and oral medications, as well as biological and phototherapy. Dr. Forman is one of the few Tampa dermatologists to offer narrowband light therapy, which uses pharmaceutical grade light to suppress psoriasis. Hes also one of the few board-certified dermatologists in the U.S. to use the SRT-100 radiotherapy to treat basal cell carcinoma, the most common form of skin cancer.

View post:
Tampa dermatologist says SPF a top anti-aging agent

Googles Anti-Aging Company Calico Gets A Website

As you may recall, Google announced the formation of a new company called Calico lat fall, aimed at studying aging and its effects on health and well-being (or as some us put it, keeping us from dying).

SFGate discovered (via Business Insider) that Calico now has a website up at CalicoLabs.com.

Heres what it says:

Were tackling aging, one of lifes greatest mysteries.

Calico is a research and development company whose mission is to harness advanced technologies to increase our understanding of the biology that controls lifespan. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives. Executing on this mission will require an unprecedented level of interdisciplinary effort and a long-term focus for which funding is already in place.

It goes on to say that Calico is made up of scientists from the fields of medicine, drug development, molecular biology, and genetics, and shows off the team:

It also says, it will post career opportunities as they become available, and that its ability to handle press inquiries will be limited, but does include an email address for such inquiries.

Image via Calico

Read this article:
Googles Anti-Aging Company Calico Gets A Website

Chemistry- Chemical Reactions and Mole Concepts-Part 1(What is a Chemical Reaction) KERALA Std X – Video


Chemistry- Chemical Reactions and Mole Concepts-Part 1(What is a Chemical Reaction) KERALA Std X
http://staugustintution.blogspot.in/ Chemistry- Chemical Reactions and Mole Concepts-Part 1(What is a Chemical Reaction) KERALA SSLC Std X http://staugustintution.blogspot.in/

By: free tuition@SATC

See the original post:
Chemistry- Chemical Reactions and Mole Concepts-Part 1(What is a Chemical Reaction) KERALA Std X - Video

More intensive interventions needed to combat severe obesity in teens

PUBLIC RELEASE DATE:

11-Aug-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, August 11, 2014 -- Nearly 6% of all children and teens in the U.S. are severely obese, and the prevalence of severe obesity is increasing faster than that of moderate obesity or overweight. This is an alarming trend as about 90% of these youths will grow up to be obese adults. The serious health problems associated with severe obesity and the poor long-term prognosis and quality of life projected for these children and teens demand more serious consideration of safe and effective treatment options that go beyond diet and lifestyle modifications, as proposed in an Editorial published in Childhood Obesity, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Childhood Obesity website at http://online.liebertpub.com/doi/full/10.1089/chi.2014.1041 until September 12, 2014.

In "Pediatric Severe Obesity: Time to Establish Serious Treatments for a Serious Disease," Stephen R. Daniels, MD, PhD, University of Colorado School of Medicine and Children's Hospital Colorado (Aurora), and Aaron S. Kelly, PhD, University of Minnesota Medical School and Children's Hospital (Minneapolis), note that while healthy lifestyle changes made during childhood may be quite helpful in weight reduction, these less intensive types of approaches tend to be less effective in treating severely obese teenagers. According to the authors, better access to specialty medical weight management programs, pharmacotherapy, and weight loss surgery are all important components of a more comprehensive strategy to combat severe obesity among teens.

"Drs. Daniels and Kelly are performing a vital service by directing our attention to this serious and increasingly prevalent problem," says David L. Katz, MD, MPH, Editor-in-Chief of Childhood Obesity and Director, Yale University Prevention Research Center. "We need commensurately serious solutions which I believe can include lifestyle interventions, but only of adequate scope and intensity. Just as lifestyle has been proven a worthy alternative to coronary bypass surgery, our sons and daughters deserve alternatives to bariatric surgery in combating this problem that our culture has handed them."

###

About the Journal

Childhood Obesity is a bimonthly journal, published in print and online, and the journal of record for all aspects of communication on the broad spectrum of issues and strategies related to weight management and obesity prevention in children and adolescents. The Journal includes peer-reviewed articles documenting cutting-edge research and clinical studies, opinion pieces and roundtable discussions, profiles of successful programs and interventions, and updates on task force recommendations, global initiatives, and policy platforms. It reports on news and developments in science and medicine, features programs and initiatives developed in the public and private sector, and includes a Literature Watch. Tables of content and a sample issue may be viewed on the Childhood Obesity website at http://www.liebertpub.com/chi.

About the Publisher

Read more from the original source:
More intensive interventions needed to combat severe obesity in teens